-
公开(公告)号:US20130143827A1
公开(公告)日:2013-06-06
申请号:US13751693
申请日:2013-01-28
申请人: Wyeth LLC
摘要: A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided.
-
公开(公告)号:US20200338199A1
公开(公告)日:2020-10-29
申请号:US16946998
申请日:2020-07-14
申请人: Wyeth LLC
发明人: Chandra A Webb , Julie Zerfas
摘要: The invention provides methods for preparing pharmaceutical formulations for injection such that upon injection the formulation does not cause erythrocyte agglutination, hemolysis, and/or cell shrinkage. To prevent agglutination, a pharmaceutical formulation ready for injection needs to have a sufficient ionic strength. To prevent hemolysis or cell shrinkage, a pharmaceutical formulation ready for injection needs to be about isotonic with respect to plasma. The invention provides methods that prepare pharmaceutical formulations for injection that have both the sufficient ionic strength to prevent agglutination and the requisite tonicity to prevent significant hemolysis or cell dehydration or shrinkage. The present methods involve the use of sodium chloride solutions that are about 25 mM to about 150 mM for reconstituting lyophilized cakes (or other non-liquid pharmaceutical formulations) into solution or for diluting pharmaceutical formulation solutions.
-
公开(公告)号:US20200325441A1
公开(公告)日:2020-10-15
申请号:US16907799
申请日:2020-06-22
申请人: Wyeth LLC
摘要: The invention relates to methods of improving protein production, e.g., large-scale commercial protein production, e.g., antibody production, utilizing a modified fed-batch cell culture method comprising a cell growth phase and a polypeptide production phase. The modified fed-batch cell culture method combines both cell culture perfusion and fed-batch methods to achieve higher titers of polypeptide products. Because the modified fed-batch cell culture method of the invention produces higher polypeptide product titers than fed-batch culture alone, it will substantially improve commercial-scale protein production. The invention also relates to a perfusion bioreactor apparatus comprising a fresh medium reservoir connected to a bioreactor by a feed pump, a recirculation loop connected to the bioreactor, wherein the recirculation loop comprises a filtration device, e.g., ultrafiltration or microfiltration, and a permeate pump connecting the filtration device to a permeate collection container.
-
公开(公告)号:US10376505B2
公开(公告)日:2019-08-13
申请号:US16219159
申请日:2018-12-13
申请人: Wyeth, LLC
发明人: Syed M. Shah , Christopher Richard Diorio , Eric C. Ehrnsperger , Xu Meng , Kadum A. Al Shareffi , Jonathan Marc Cohen
IPC分类号: A61K31/485 , A61K9/20 , C07D489/08 , A61K9/28 , A61K47/12 , A61K47/20 , A61K9/00
摘要: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
-
公开(公告)号:US20190202873A1
公开(公告)日:2019-07-04
申请号:US16359267
申请日:2019-03-20
申请人: Wyeth LLC
发明人: Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G.K. Donald , Maninder K. Sidhu , Narender Kumar Kalyan , Justin Keith Moran , Mark Edward Ruppen , Michael James Flint
摘要: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号:US10238640B2
公开(公告)日:2019-03-26
申请号:US15349101
申请日:2016-11-11
申请人: Wyeth LLC
发明人: Jay Dickerson , William Mark , Annabelle Trimmer , David Jaeger , Amanda Alley
IPC分类号: A61K9/00 , A61K9/10 , A61K31/00 , A61K45/06 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/26 , A61K47/36 , A61K47/38 , A61K31/137 , A61K31/192 , A61K31/4402
摘要: An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously.
-
公开(公告)号:US10196433B2
公开(公告)日:2019-02-05
申请号:US15587708
申请日:2017-05-05
申请人: Wyeth LLC
发明人: Stephen Berasi , Robert Vincent Martinez , Michael John Cain , John Martin Wozney , Howard Joel Seeherman , Zong Sean Juo , Valerie Perrine Calabro , Christopher Todd Brown
IPC分类号: A61K38/16 , A61K38/17 , A61K38/19 , C07K14/00 , C07K14/435 , C07K14/46 , C07K14/47 , C07K14/475 , C12N15/12 , C12N15/00 , C07K14/51
摘要: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
-
公开(公告)号:US10035788B2
公开(公告)日:2018-07-31
申请号:US15463998
申请日:2017-03-20
申请人: Wyeth LLC
发明人: Qinghong Lu , Mannching Sherry Ku , Warren Chew , Gloria Cheal , Anthony F. Hadfield , Mahmoud Mirmehrabi
IPC分类号: A61K31/4709 , C07D401/12 , C07C57/145 , C07C51/41
CPC分类号: C07D401/12 , A61K31/4709 , C07C51/412 , C07C57/145
摘要: The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
-
公开(公告)号:US20180162937A1
公开(公告)日:2018-06-14
申请号:US15883759
申请日:2018-01-30
申请人: WYETH LLC
发明人: Erwin R. BOGHAERT , Nitin K. DAMLE , Philip Ross HAMANN , Kiran KHANDKE , Arthur KUNZ , Kimberly A. MARQUETTE , Lioudmila TCHISTIAKOVA , Davinder GILL , Sreekumar R. KODANGATTIL
CPC分类号: C07K16/28 , A61K47/6849 , A61K51/1027 , A61K2039/505 , A61P35/00 , C07K14/82 , C07K16/30 , C07K16/32 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/77 , C07K2317/92
摘要: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
-
公开(公告)号:US09850301B2
公开(公告)日:2017-12-26
申请号:US15230430
申请日:2016-08-07
申请人: Wyeth LLC
发明人: Edward Roland LaVallie , Lisa Anne Collins-Racie , Christopher John Corcoran , Lioudmila Gennadievna Tchistiakova , John Adam Nowak , Riyez Karim , Xiang-Yang Tan , Kimberly Ann Marquette , Geertruida Machteld Veldman
IPC分类号: C12N1/21 , C12N1/11 , C12N1/13 , C12N1/19 , C12N5/10 , C12N5/16 , C12N15/11 , C12N15/13 , C12N15/63 , C07K16/22 , A61K39/00
CPC分类号: C07K16/22 , A61K39/395 , A61K2039/505 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.
-
-
-
-
-
-
-
-
-